National press ad, London Underground poster for GSK's NiQuitin CQ smoking cessation lozenge deemed "misleading" by Britain's Advertising Standards Authority in Sept. 11 ruling. Ad watchdog upheld a complaint brought by rival Pharmacia Consumer Healthcare challenging claim NiQuitin CQ can "triple your chances of success." In its defense, GSK maintains claim was based on a study of over 1,800 UK and U.S. smokers, which found 23.6% of participants in active arm achieved cessation, compared with 10.2% of those in control arm. GSK rounded up the odds ratio of 2.76 to give the "triple" claim. However, ASA concludes the inflated ratio "did not justify the claim" and recommends GSK amend the ads with help from the Committee of Advertising Practice Copy Advice...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.
As Chief Medical and Scientific Officer, Vinay Prasad will advise the FDA Commissioner on cross-cutting issues, provide strategic leadership and be a public face of the agency.
Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.
